Full-Time

Duchenne Area Manager

Confirmed live in the last 24 hours

Sarepta

Sarepta

501-1,000 employees

Develops genetic medicines for rare diseases

Compensation Overview

$148k - $185k/yr

Senior

Seattle, WA, USA + 1 more

More locations: Phoenix, AZ, USA

Candidates must live in either the Seattle WA or Phoenix AZ areas due to travel needs for the role.

Category
Field Sales
Sales & Account Management
Required Skills
Salesforce
Requirements
  • Bachelor’s Degree required
  • 5+ years of field experience in biotech industry, preferably in orphan diseases
  • Demonstrated understanding of healthcare regulatory and enforcement environments, specifically in orphan or rare disease
  • Excellent consultative selling skills with proven record of performance
  • Strong verbal and written communication skills
  • Valid driver’s license and in good standing
  • Ability to travel up to 70%
  • Advanced use of MS Office Suite and Veeva/Salesforce
Responsibilities
  • Promotes safe and effective use of Sarepta therapies in accordance with the product label and company training and policies
  • Assume responsibility for enrollment form attainment for the four currently approved products (and other launch products when applicable) within a defined geography
  • Build and maintain strong relationships with key HCPs in identified Sites of Care by educating and selling our four marketed products
  • Build strong referral networks outside the sites of care by educating and selling our four marketed products with the ultimate goal of identifying new patients or patients diagnosed and lost to follow up
  • Execute a consistent consultative selling model to achieve optimum results and be recognized as a leader in clinical selling skills
  • Develop strategic account plans with clearly defined sales and executional objectives, ensuring efficient and comprehensive coverage of assigned geography
  • Where appropriate drives identification of naïve DMD patients by educating HCPs to ensure timely diagnosis and access to care
  • Leads HCP education on importance of genetic testing, access, and amenability
  • Leads HCP education on the antibody assay, how to access and successful pull through
  • Successful outreach to all priority leads based on current business strategy
  • Stays current on the DMD environment; maintains advanced knowledge of disease, local drivers, treatment and referral patterns, key account profiles, influence patterns, reimbursement, and barriers to optimal care
  • Ensures appropriate resource allocation to meet customer needs and address gaps in DMD understanding and care
  • Exercises sound judgment and adheres to relevant regulatory and compliance guidelines and company policies
  • Works collaboratively across functional areas to achieve common goals and address issues
  • Challenges convention, communicates thoughts and ideas around best practices and best approaches within the DAM team
  • Assumes responsibility for projects and other duties, as requested by management
Desired Qualifications
  • Neuromuscular, Pediatric Neurology or other specialty experience preferred
  • Product launch experience highly desired
  • Track record of consistently exceeding sales goals
  • Demonstrates passion for improving DMD patient care delivery and keeps patient at the center of all efforts
  • Embraces and adopts new technologies/techniques and continuous learning

Sarepta Therapeutics develops precision genetic medicines aimed at treating rare diseases, particularly focusing on conditions like Duchenne muscular dystrophy (DMD). Their products work by utilizing gene therapies that target the underlying genetic causes of these diseases, with ongoing research into other conditions such as limb-girdle muscular dystrophy (LGMD) and Charcot-Marie-Tooth (CMT) disease. What sets Sarepta apart from its competitors is its strong emphasis on R&D and its commitment to expediting the drug development process, which allows them to bring therapies to market more quickly. The company's goal is to enhance the lives of patients with rare genetic disorders by providing effective treatments and to establish a significant gene therapy manufacturing capacity to meet global needs.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA's gene therapy approval could expedite Sarepta's therapy approvals.
  • Global rare disease treatment market is projected to grow at 11.3% CAGR until 2030.
  • Advancements in CRISPR technology may enhance Sarepta's gene therapy efficacy.

What critics are saying

  • Increased competition from emerging biotech firms like GenEdit threatens market share.
  • Patent infringement lawsuit by Nippon could lead to financial liabilities.
  • $600 million credit facility may increase financial risk if revenue targets aren't met.

What makes Sarepta unique

  • Sarepta focuses on precision genetic medicines for rare diseases, a niche market.
  • The company leads in Duchenne muscular dystrophy treatment with innovative gene therapies.
  • Sarepta's strategic partnerships enhance its R&D capabilities and market reach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Wellness Program

Company News

Business Wire
Feb 15th, 2025
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has closed on a $600 mil

MarketBeat
Dec 7th, 2023
Great Point Partners LLC Invests $14.16 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Great Point Partners LLC invests $14.16 million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT).

JD Supra
Feb 9th, 2022
Sarepta Therapeutics had issues with breach of the nondisclosure agreement on Jul 13th 21'.

On July 13, 2021, Nippon filed a patent infringement lawsuit against Sarepta in Delaware, including claims for breach of the nondisclosure agreement.

American Chemical Society
Feb 5th, 2022
GenEdit is developing gene-editing therapies for neuromuscular diseases

Gene-editing pioneer Sarepta Therapeutics will use GenEdit’s polymer nanoparticle delivery system to develop gene-editing therapies for neuromuscular diseases.

Parent Project Muscular Dystrophy
Jan 5th, 2022
Sarepta Therapeutics launched update that SRP-5051-201, the MOMENTUM study on Jan 5th 22'.

Sarepta Therapeutics has shared an update that SRP-5051-201, the MOMENTUM study (NCT04004065), is now recruiting Part B. MOMENTUM is a Phase 2, two-part, multiple-ascending-dose study of SRP-5051 for dose determination, then dose expansion, in patients with Duchenne muscular dystrophy amenable to exon 51-skipping treatment.